Current Report Filing (8-k)
April 09 2019 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 4, 2019
Cocrystal
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38418
|
|
35-2528215
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
19805
N. Creek Parkway
Bothell,
WA
|
|
98011
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (786) 459-1831
(Former
name or former address, if changed since last report.): N/A
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
(d)
On
April 4, 2019, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed
Dr. Anthony Japour as a director to fill a vacancy on the Board, effective immediately. Dr. Japour was designated by Dr. Raymond
Schinazi, our principal stockholder, pursuant to the Stockholder Rights Agreement, dated November 24, 2014. Dr. Japour was also
appointed as a member of the Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective
immediately.
Anthony
Japour, M.D., 59, has served as a Medical Director of ICON plc, a global provider of outsourced drug development and commercialization
solutions and services to the pharmaceutical, biotechnology, medical device and government and public health organizations, since
February 2016. Prior to that, from April 2012 to February 2016, Dr. Japour worked as an internal medicine physician at Elite Health
Medical Group in Miami, Florida, where he specialized in infectious diseases. Dr. Japour is also the owner and director of Anthony
Japour and Associates, Medical and Scientific Consulting, Inc., a medical and scientific consulting firm he established in November
2006.
There
are no related party transactions between the Company and Dr. Japour reportable under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Cocrystal Pharma, Inc.
|
|
|
|
Date: April 9, 2019
|
By:
|
/s/
James Martin
|
|
Name:
|
James Martin
|
|
Title:
|
Chief Financial Officer
|
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024